Home > Insider Trading > Filing (0001209191-23-049013)

Filing Details

Accession Number:: 0001209191-23-049013
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-09-11 19:05:01
Reporting Period:: 2023-09-07

Accepted Time:: 2023-09-11 19:05:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1231457	Genelux Corp	GNLX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1937513	Aladar Szalay	C/O Genelux Corporation, 2625 Townsgate Road, Suite 230 Westlake Village CA 91361		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-09-07	9,938	$24.12	159,555	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2023-09-07	2,508	$25.34	157,047	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2023-09-08	13,672	$22.78	143,375	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2023-09-08	8,523	$23.49	134,852	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2023-09-08	2,636	$24.19	132,216	No	4	S	Indirect	By Spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	32,167	Direct
Common Stock	2,258,760	Indirect	By Trust
Common Stock	550,000	Indirect	By Trust
Common Stock	1,589,577	Indirect	By Trust

Footnotes

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $23.79 to $24.55, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The Form 3 filed by the reporting person on January 25, 2023 and the Form 4 filed by the reporting person on January 30, 2023 inadvertently overstated the amount of securities beneficially owned by one share.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $25.03 to $25.55, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $22.16 to $23.1561, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $23.16 to $24.155, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $24.165 to $24.205, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
Shares held by The Szalay 2009 Irrevocable Trust.
Shares held by The Szalay 2010 Children's Trust.
Shares held by The Szalay 2010 Retained Annuity Trust.